Meta-analyses have shown that the amount of weight regained after stopping treatment is typically proportional to the initial weight loss, and lifestyle interventions become increasingly difficult to maintain once the medication is discontinued (Berg et al., 2025)
Whether these individuals have a predisposition for PanIN progression that could be uniquely vulnerable to GLP-1 receptor agonism remains unknown
Factors including tablet dissolution time, saliva production, and individual tissue permeability influence absorption rates
These include: Acute gallbladder disease (added to warning label in March 2022) Acute problems Acute pancreatitis Diabetic retinopathy complications in patients with type 2 Diabetes Gastrointestinal obstruction Ileus (added to the warning label in September 2023) Heart rate increase Hypoglycemia Possible thyroid tumors, including cancer Severe allergic reactions and hypersensitivity reactions, including anaphylaxis and angioedema Suicidal thoughts or behavior If you are taking Wegovy or any other GLP-1 drug like Mounjaro or Rybelsus , contact your doctor if you experience new or worsening side effects
The support team can connect licensed professionals with verified research-grade suppliers and provide guidance on the documentation standards commonly required for institutional procurement
